A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin
A salvage treatment with combination of docetaxel and epirubicin in patients with unresectable, metastatic gastric cancer after fluoropyrimidine failure : A HER2 status-based study
Metastatic Advanced Gastric Cancer
OTHER: Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
disease control rate according to the RECIST v1.1, The primary outcome of the current study is the disease control according to the HER2 status. That is, the % of the patients who maintains at least stable disease by RECIST v1.1 at the time of the second tumor evaluation which will be taken at 6\~8 weeks later after the first evaluation. The comparison will be done by Pearsons's chi-square test., at 6~8 weeks later after the first evaluation
A salvage treatment with combination of docetaxel and epirubicin in patients with unresectable, metastatic gastric cancer after fluoropyrimidine failure : A HER2 status-based study